NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets close in 4 hrs 9 mins

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
39.33+0.49 (+1.27%)
As of 11:50AM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close38.84
Bid39.03 x 100
Ask39.05 x 100
Day's Range38.43 - 39.36
52 Week Range31.25 - 55.15
Avg. Volume1,112,661
Market Cap3.42B
PE Ratio (TTM)-27.07
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research5 days ago

    NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint

    The study did not achieve the pre-specified primary endpoint, which was the change from baseline in the Yale Global Tic Severity Scale (YGTSS) at Week 8 (P=0.18). Due to the fact that a number of the same investigators from the T-Forward study are also taking part in the T-Force GREEN study of INGREZZA™ in children and adolescents with Tourette syndrome, the company did not release many details of the results in order to avoid potentially introducing assessor bias into the T-Force GREEN study. Tourette syndrome (TS) is a childhood neuropsychiatric disorder that is characterized by repetitive movements and unwanted sounds that are not easily controlled.

  • CNBC7 days ago

    After hours buzz: CSX, UAL, GIMO & more

    Check out Tuesday's after hours buzz: CSX, UAL, GIMO & more

  • Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down
    Investor's Business Daily7 days ago

    Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down

    Neurocrine's Tourette drug failed in a trial and the FDA approved a generic narcolepsy drug rivaling Jazz, and both stocks fell late.